LG AI Research, part of the South Korean LG Group, has announced its latest artificial intelligence model, EXAONE Path 2.0, for pathology studies.

This news comes from Yonhap.

The lab revealed that compared to the earlier version 1.0, EXAONE Path 2.0 offers improved accuracy in analyzing and predicting genetic mutations, gene expression patterns, and minor structural changes in human cells and tissues based on pathological image analysis.

It is noted that the model has been trained on over 10,000 datasets, encompassing visualization and multi-omics, enabling it to predict gene activity solely through image analysis without the need for expensive genomic testing.

“With EXAONE Path 2.0, genetic testing can be completed in under a minute, compared to over two weeks previously required. This will help save crucial time for treating cancer patients,” said lead researcher Pak Yong-min from LG AI Research.

He added that doctors and pharmaceutical companies can utilize EXAONE Path 2.0 for rapid analysis of pathological images of cancer patients, identifying genetic mutations and selecting appropriate targeted therapies.

As reported by Ukrinform, the Chinese company DeepSeek has also released an updated AI model, DeepSeek R1, intensifying its competition with OpenAI, the developer of the popular chatbot ChatGPT.